Table 2.

Effect of alirocumab on low-density lipoprotein cholesterol (LDL-C), secondary lipid parameters, and LDL-C target levels at baseline and week 24 (intention-to-treat [ITT] analysis)

	Baseline, mean (SD), mmol/L [mg/dL]	Week 24, mean (SD), mmol/L [mg/dL]	Mean absolute change from baselinea, mean (SD), mmol/L [mg/dL]	Change from baseline to week 24a, LS mean, %	p value
LDL-C	4.7 (1.6) [180.5 (60.7)]	2.3 (1.2) [89.8 (46.0)]	− 2.3 (1.4) [− 90.3 (53.8)]	− 48.6	< 0.0001
Non-HDL-C	5.5 (1.9) [213.9 (72.2)]	2.9 (1.4) [113.6 (52.8)]	− 2.6 (1.7) [− 101.9 (65.5)]	− 45.8	< 0.0001
HDL-C	1.3 (0.5) [50.8 (19.7)]	1.4 (0.4) [52.6 (16.6)]	0.1 (0.3) [2.0 (13.1)]	7.1	< 0.0001
Total cholesterol	6.9 (2.0) [266.6 (76.1)]	4.3 (1.4) [167.2 (55.2)]	− 2.6 (1.7) [− 99.5 (64.6)]	− 35.7	< 0.0001
TGs	2.9 (4.3) [256.8 (377.9)]	2.1 (2.2) [186.9 (191.8)]	− 0.9 (3.5) [− 76.6 (305.7)]	− 11.0	< 0.0001
Median (Q1:Q3)	2.0 (1.5:3.1) [178.0 (129.0:268.0)]	1.6 (1.2:2.5) [144.0 (106.0:218.0)]	− 0.3 (− 1.0:0.1) [− 29.0 (− 85.0:9.0)]

HDL-C high-density lipoprotein cholesterol, LS least squares, SD standard deviation, TG triglyceride

^aData presented for the modified ITT population